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ined the impact of changes in private drug plan formulary design
on the health of private plan beneﬁciaries. METHODS: A search
of the medical literature was conducted using the PubMed search
engine. Search terms included combinations of reimbursement,
formulary, plan, payer, restriction, cost, and adherence. The
‘related articles’ feature in PubMed was also used to identify
relevant papers. RESULTS: While no published studies of Cana-
dian employer-sponsored drug plans were identiﬁed, there were
15 North American studies that focused on the effects of changes
in drug plan design. This body of research demonstrated three
key points. Cost-sharing initiatives resulted in a reduction, or
complete cessation, of medication consumption, including
drugs deemed “essential”, and that decreased adherence to drug
therapy can actually lead to the increased use of other more
expensive health care resources. On the other hand, higher levels
of medication adherence, which increased drug costs, were asso-
ciated with lower overall health care costs. Employee satisfaction
with their employer drug plan decreased when cost-containment
measures were implemented and this is a problem for employers
since drug plan changes typically involved increasing fees or
imposing more restrictions to access. CONCLUSION: A short-
term focus on controlling drug costs is likely to have negative
consequences on the health, productivity and satisfaction of plan
members. If changes to drug plans are not properly assessed,
there can be undesirable and expensive consequences for plan
members and employers. Employers need a longer term frame-
work to guide and support health plan decision-making that
avoids sudden or drastic changes to health beneﬁts. Careful
consideration of drug plan design and cost-sharing can improve
medication adherence, health outcomes, employee satisfaction,
and costs.
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OBJECTIVES: While pharmaceuticals can signiﬁcantly improve
the health of patients and help to mitigate health-related inequi-
ties within a population, their rising prominence within health
systems is not without challenges. This paper explores health
related aspects of pharmaceutical policy in Australia, Canada,
Germany, The Netherlands, New Zealand, the UK and the
United States. METHODS: Drawing on published goals for
national policies, we developed a framework for gauging
pharmacare system performance. We review policy structures
and investigate system performance using preliminary indicators
drawn from the 2007 Commonwealth Fund Survey. Survey
responses to questions related to accessibility, affordability, and
appropriateness are compared across countries and stratiﬁed by
age, income and morbidity. RESULTS: Shares of populations
reporting prescription drug use were lowest in Germany and
highest in the US. Pharmaceutical use displayed expected age
gradients in all countries and expected income gradients in all but
Germany and the US. Cost-related non-adherence was most fre-
quent in the US and Australia, and relatively unlikely among
elderly populations. Relatively few patients reported prescribing
errors, with no signiﬁcant differences across countries. Out-of-
pocket drug costs were highest in the US and Canada. From 1995
to 2005, pharmaceutical expenditures outpaced health care and
GDP in all countries except New Zealand. Expenditure grew
most quickly in the US. CONCLUSION: Though no country
appears uniformly strong in all areas of pharmacare policy,
several appear to have done well to manage difﬁcult tensions in
the pharmaceutical sector.
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OBJECTIVE: Snyder and King (2007) developed a theoretical
model of ﬁrm behavior in which research and marketing activi-
ties are complements rather than substitutes. Public policy debate
frequently makes the implicit assumption that the two activities
are substitutes. In this paper the author uses ﬁnancial reports of
Fortune 200 pharmaceutical ﬁrms to examine the evidence for
Snyder and King’s theoretical model. METHODS: We extract
research and marketing expenditure totals from the quarterly
ﬁlings of the eight largest U.S. based pharmaceutical companies.
We also create a comparator list of non-pharmaceutical compa-
nies matched for size and using pre-speciﬁed exclusion criteria.
Univariate analysis is used to test whether pharmaceutical
companies are systematically different from the comparator com-
panies. Simple regression analysis is used to test whether com-
panies with higher research/revenue ratios have higher or lower
marketing/revenue ratios. RESULTS: Pharmaceutical ﬁrms spend
a greater share of revenue on both marketing and R&D than the
comparator ﬁrms. The share spent on marketing is similar to a
subgroup of the comparator ﬁrms. The share spent on research
is uniquely high. Pharmaceutical ﬁrms are also unique in their
combination of high marketing and high research spending.
Regression analysis shows no signiﬁcant relationship (positive or
negative) between research and marketing expenditure. CON-
CLUSION: Empirical analysis provides limited support to the
theory developed in Snyder and King (2007). The absence of
signiﬁcant regression results may be due to the time lag between
development and approval for sale.
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OBJECTIVE: The RIZIV/INAMI, the Belgian third-party payer,
aims to set reimbursement tariffs at a level that reﬂects costs of
orthotic braces. In the absence of publicly disclosed information
on the cost structure of braces, estimating production and distri-
bution costs of braces is valuable to reimbursement agencies with
a view to setting tariffs. The aim of this study is to calculate the
cost of production and distribution of a prefabricated hard neck
brace and a prefabricated hard knee brace, and to explore
whether Belgian tariffs and actual retail prices correspond with
estimated costs of these two braces. METHODS: The cost model
took into account manufacturing costs, general overhead,
research and development, warehousing, proﬁt and distribution
margins. Data were gathered from manufacturers, a visit to a
production site, desk research, a decomposition of ﬁnished prod-
ucts and interviews with stakeholders. The price year was 2007.
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